Pseudo-endocrine Disorders: Recognition, Management, and Action
- PMID: 39749108
- PMCID: PMC11694709
- DOI: 10.1210/jendso/bvae226
Pseudo-endocrine Disorders: Recognition, Management, and Action
Abstract
"Pseudo-endocrine disorders" refer to proposed conditions that have never been scientifically proven to exist but, due to widespread misinformation available on the internet and other media, are relatively commonly diagnosed and treated with equally unproven and sometimes dangerous treatments. Adrenal fatigue is a nonexistent condition that supposedly results from adrenal exhaustion and atrophy due to chronic stress and has been promoted as a potential explanation for a variety of symptoms. Testing consists of nonvalidated online surveys and salivary cortisol profiles while treatment is not evidence-based at best and can be dangerous. Wilson's syndrome and reverse T3 syndrome are also nonexistent conditions that supposedly result from impaired T4 to T3 conversion and competition of excess reverse T3 with T3 for T3 receptors. Testing involves measurement of axillary temperature and treatment consists of T3 therapy, often at very high and dangerous doses. Hypogonadism ("low T") is frequently diagnosed in "men's health" clinics and other venues without actual hormone testing or further evaluation and is often treated with supraphysiologic testosterone therapy that suppresses endogenous gonadal testosterone and sperm production, leads to a lifelong need for testosterone therapy, and may have numerous other harmful effects. Low-dose naltrexone (LDN) therapy has been proposed as a treatment for multiple disorders including autoimmune conditions and other disorders resulting from aberrant immune mechanisms, but there is no valid evidence that LDN has any benefits. Management of patients with pseudo-endocrine disorders must involve careful listening, patient education, healthy lifestyle measures, and honesty, encouragement, and compassion.
Keywords: Wilson's syndrome; adrenal fatigue; low-dose naltrexone; reverse T3 syndrome.
© The Author(s) 2024. Published by Oxford University Press on behalf of the Endocrine Society.
Similar articles
-
OFF-LABEL USE AND MISUSE OF TESTOSTERONE, GROWTH HORMONE, THYROID HORMONE, AND ADRENAL SUPPLEMENTS: RISKS AND COSTS OF A GROWING PROBLEM.Endocr Pract. 2020 Mar;26(3):340-353. doi: 10.4158/PS-2019-0540. Endocr Pract. 2020. PMID: 32163313
-
[Standard technical specifications for methacholine chloride (Methacholine) bronchial challenge test (2023)].Zhonghua Jie He He Hu Xi Za Zhi. 2024 Feb 12;47(2):101-119. doi: 10.3760/cma.j.cn112147-20231019-00247. Zhonghua Jie He He Hu Xi Za Zhi. 2024. PMID: 38309959 Chinese.
-
Supraphysiological cyclic dosing of sustained release T3 in order to reset low basal body temperature.P R Health Sci J. 2006 Mar;25(1):23-9. P R Health Sci J. 2006. PMID: 16883675 Review.
-
Erythrodermic Presentation of Atopic Dermatitis in a Patient with Secondary Adrenal Insufficiency Caused by Oral Glucocorticosteroid Abuse.Acta Dermatovenerol Croat. 2023 Nov;31(2):103-105. Acta Dermatovenerol Croat. 2023. PMID: 38006372
-
THERAPY OF ENDOCRINE DISEASE: T4 + T3 combination therapy: is there a true effect?Eur J Endocrinol. 2017 Dec;177(6):R287-R296. doi: 10.1530/EJE-17-0645. Epub 2017 Aug 30. Eur J Endocrinol. 2017. PMID: 28855267 Review.
References
-
- McDermott MT, ed. Management of Patients with Pseudo-Endocrine Disorders. A Case-Based Pocket Guide. Springer Nature; 2019.
-
- Warraich H. Dr. Google is a liar. New York Times, December 16, 2018; Page A19 of the New York Edition. https://www.nytimes.com/2018/12/16/opinion/statin-side-effects-cancer.ht...
-
- Schwartz LM, Woloshin S. Low “T” as in “template”. how to sell disease. JAMA Intern Med. 2013;173(15):1460‐1462. - PubMed
-
- Pryor L. How to counter the circus of pseudoscience. New York Times, January 5, 2018. https://www.nytimes.com/2018/01/05/opinion/doctors-naturopaths-health-sc...
LinkOut - more resources
Full Text Sources